A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
NCT07748208
This study is recruiting at 9 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will evaluate the safety of inavolisib in combination with fulvestrant, with or without palbociclib, in participants with PIK3CA-mutated, HR+, HER2-negative ABC and type 2 diabetes.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
- Diabetes Type II
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Hoffmann-La Roche
- Last updated on ClinicalTrials.gov
- October 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
District of Columbia · 1
- MedStar Washington Hosp Center · Washington D.C., DC
Georgia · 3
- Emory University Hospital · Atlanta, GA
- Emory University Hospital Midtown · Atlanta, GA
- Grady Memorial Hospital · Atlanta, GA
Nebraska · 2
- Nebraska Cancer Specialists St Francis - Grand Island · Grand Island, NE
- Nebraska Cancer Specialists · Omaha, NE
New York · 2
- NYU Langone Hospital Long Island Clinical Research · Mineola, NY
- NYU Langone?s Perlmutter Cancer Center - 160 E 34th St · New York, NY
West Virginia · 1
- West Virginia University · Morgantown, WV
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.